FDA To Reverse HRT Black Box Warning—Here’s Why That’s a Win for Women’s Healthspans

In a move that many menopause specialists describe as “about time,” the FDA will remove the long-standing black box warning from many forms of hormone replacement therapy (HRT).¹ It’s one of the most significant regulatory shifts in women’s health in a generation—and it directly affects the tens of millions of women navigating perimenopause, menopause, and the decades that follow.

For more than 20 years, nearly every estrogen-containing product—estradiol patches, creams, gels, pills, and even low-dose vaginal estrogen—has carried the FDA’s most severe safety label, warning of elevated risks of stroke, blood clots, dementia, and breast cancer. The warning was based largely on misunderstood and misreported interpretations of data from the 2002 Women’s Health Initiative.

This morning’s announcement signals an official acknowledgment of what specialists have known for years: the science has evolved, and the risks once attributed to estrogen were overstated or misunderstood.

FDA Commissioner Marty Makary, M.D., MPH, has described the boxed warning as“outdated,” “overbroad,” and a barrier to care for women who stood to benefit from modern, personalized forms of HRT. The agency’s advisory panel overwhelmingly recommended its removal earlier this year.

Removing the warning doesn’t make hormone therapy risk-free, and it doesn’t mean every woman should start estrogen tomorrow. But it does open the door to nuance—to individualized care instead of blanket fear. And importantly, it allows clinicians and patients to talk about HRT as a potential strategy to increase healthspan, not just reduce hot flashes.

Because here’s the quiet part said out loud: Estrogen does more than ease symptoms. It offers confirmed protection for your bones and urogenital system, and potentially your heart and brain—the infrastructures of healthy aging.

UTI Prevention & Urogenital Health

When estrogen levels drop during perimenopause and menopause, the tissues of the vagina and lower urinary tract undergo structural and microbial changes that increase the likelihood of urinary tract infections. 

The lining thins, lubrication declines, protective lactobacilli disappear, and the environment becomes more favorable for bacteria that cause infections.²

Urinary tract infections are among the most common bacterial infections in women. Up to 30 percent of postmenopausal women experience recurrent infections each year, with recurrence rates rising to about 50 percent within 6–12 months of the initial infection.³

Recurrent UTIs aren’t just annoying;  they can cause ongoing irritation and thinning of the bladder lining, which may lead to lasting pelvic pain and raise the risk of problems like an overactive bladder, urine leaks, and antibiotic-resistant infections.⁴

These ongoing changes are part of a broader condition known as Genitourinary Syndrome of Menopause (GSM)—a collection of symptoms driven by estrogen loss that affects both vaginal and urinary health. GSM affects up to 70 percent of women after menopause, and unlike hot flashes, it doesn’t go away on its own.^{5 6}

GSM symptoms such as vaginal dryness, pain with sex, burning with urination, urgency, and frequent UTIs tend to worsen over time, taking a toll on sexual comfort, confidence, and body image.⁷ Studies show that the thinning and weakening of urogenital tissues seen with GSM also increase susceptibility to infection, urinary frequency, and incontinence, and often occur alongside pelvic floor disorders.⁸

Restoring estrogen can reduce UTI risk—especially through low-dose vaginal formulations. It rebuilds the mucosal barrier, lowers vaginal pH, and brings lactobacilli back into the picture. Clinically, that means fewer UTIs, less irritation, and meaningful relief from GSM and it’s long-term impacts. 

Stronger Bones

Once estrogen levels fall during menopause, bone turnover speeds up—old bone breaks down faster than new bone can form. That’s why fractures and osteoporosis become so common in women after midlife. Bone loss typically starts one to three years before the final menstrual period, with women losing about 1–2 percent of bone mass per year and up to 10–12 percent over the following decade.^{9 10 11}

The good news is that hormone therapy may slow this process when started at the right time. 

In the 2022 U.S. Preventive Services Task Force (USPSTF) evidence review, women taking estrogen alone had 388 fewer fractures per 10,000 women over about seven years compared with a placebo, while those on estrogen plus progestin had 44 fewer fractures per 10,000 over around 5 years compared with a placebo.¹²

The original WHI trial showed that combined estrogen‑progestin therapy (using conjugated equine estrogen and medroxyprogesterone acetate) reduced total fractures by 24 percent and increased hip bone density by nearly 4 percent over three years. Subsequent trials show similar bone‑density gains with modern transdermal estradiol and micronized progesterone, which are now the preferred formulations due to a more favorable safety profile.¹³

A comprehensive 2021 umbrella review in PLoS Medicine, pooling results from 60 systematic reviews, reinforced these findings—showing consistent gains in bone mineral density and a significant reduction in both vertebral and non-vertebral fractures among hormone-therapy users.¹⁴ And a new 2025 population‑based study tracking more than three million U.K. women reported that current users of estrogen therapy had a 24–25 percent lower fracture risk compared with never‑users, while that benefit waned gradually after stopping.¹⁵

Important caveat: Estrogen is not approved as a treatment for osteoporosis, but it may be considered for prevention, particularly for women who also need MHT for hot flashes or entered menopause early. Given that fractures are a major threat to independence later in life, this is far more than a cosmetic issue — it’s a pillar of healthspan.

Mood, Emotional Stability & Overall Well-Being

Estrogen interacts with key neurotransmitter systems—including serotonin, dopamine, and norepinephrine—that govern everything from emotional resilience to reward processing to stress tolerance.¹⁶ 

When levels drop, those networks wobble, causing mood swings, irritability, heightened anxiety, and the classic “flat” or apathetic feelings which are common during the menopause transition.¹⁷

Strong new evidence shows that hormone therapy can help steady that internal circuitry, especially when started during perimenopause or soon after menopause. In a randomized clinical trial of 172 women aged 45–60, those receiving transdermal estradiol (0.1 mg/day) plus intermittent micronized progesterone were about 50 percent less likely to develop clinically significant depressive symptoms over 12 months than women on a placebo.¹⁸

A 2023 meta‑analysis of 14 randomized trials in the Journal of Psychiatric Research confirmed that estrogen therapy—alone or with progesterone—significantly improved depressive mood scores, with the strongest effects seen in perimenopausal women, where hormone fluctuations are greatest.¹⁹ These benefits appear to be linked more to stabilizing estrogen levels than to increasing hormone levels.

Real‑world data echo these findings: a 2025 U.K. cohort study of 920 women found that starting or optimizing hormone therapy was associated with a 45% reduction in mood‑symptom scores within months.²⁰

By easing mood swings and preventing depression or anxiety during menopause, estrogen therapy can help preserve emotional and cognitive resilience, lower the biological stress load that accelerates aging, and support a longer, healthier life.

Cognitive Protection

Most people don’t realize how deeply the brain relies on estrogen until it’s gone. Estrogen works in many parts of the brain, where it helps cells make energy and communicate smoothly with one another, and protects against everyday wear and tear.

Alzheimer’s disease (AD) is the most common form of dementia, and research consistently shows that women face a higher risk than men. Starting at age 45, a woman’s lifetime risk of developing AD is about 1 in 5, compared to 1 in 10 for men.²¹

Studies consistently show that menopause marks a critical inflection point for cognitive vulnerability, with decline affecting up to two‑thirds of women.²²

Women who enter menopause prematurely—under the age of 45—appear to be most at risk: One 2023 study found that women who enter menopause early have a 37 percent increased risk of dementia compared to women who enter it around the average age (around 52).²³

Newer research provides strong evidence for what’s known as the “timing hypothesis”—that the brain’s response to estrogen depends critically on when therapy begins relative to menopause.

Earlier findings from 2020 showed that initiating menopausal hormone therapy within 10 years of menopause or before age 60 was associated with a significant reduction in Alzheimer’s disease and all‑cause dementia risk, whereas starting later was linked to increased risk.²⁴

While HRT isn’t currently recommended as a dementia-prevention therapy, growing data suggest a neuroprotective role — one important factor in mid-life brain-health conversations.

Reduced Cardiovascular Risk

Before menopause, women’s estrogen naturally helps keep blood vessels more elastic and supports a healthy cholesterol balance. Once estrogen levels drop, that cardiovascular advantage fades quickly—arteries stiffen, LDL rises, and heart risk accelerates.^{25 26 27}

Recent research shows that starting hormone therapy early—within about 10 years of menopause—may improve some cardiometabolic markers such as LDL (“bad” cholesterol), especially with transdermal routes that avoid the rise in triglycerides—the fats that can raise heart risk—seen with oral estrogen. ^{28 29}

Important caveat: Major bodies currently advise against using HRT solely to prevent heart disease. The regulatory shift matters here: removing the fear-based barrier means women who could derive cardiovascular benefit won’t be prematurely steered away by outdated warnings.

A Turning Point for Women’s Health

The FDA’s decision doesn’t erase the need for thoughtful prescribing, shared decision-making, or individualized risk assessment. But it does finally bring federal labeling in line with modern evidence—and with what many experts have been advocating for years.

For women in midlife, it means conversations about HRT can shift from fear to facts. For clinicians, it means greater clarity and fewer roadblocks. And for everyone thinking about healthspan rather than just lifespan, it marks a rare moment in American healthcare where policy actually catches up to science.

If menopause is the biological cliff, estrogen has always been one of the guardrails. Today’s FDA move simply makes it easier—and safer—for women to grab onto it, to live better for longer. 

Mentioned in This Article:

Estradiol Patch

Estradiol patches can help alleviate symptoms of menopause, including hot flashes, vaginal dryness, and osteoporosis, by supplementing reduced estrogen levels.

Learn More

Bi-est cream

Hone’s Bi-est Cream is available as a 50/50 or 80/20 compound of estradiol and estriol, and is used as a topical treatment to balance hormones and alleviate menopausal symptoms like hot flashes and night sweats.

Learn More

Estriol Vaginal Cream

Cream containing Estriol, a form of the hormone estrogen that's considered gentler than estradiol, can be directly applied to relieve symptoms associated with menopause and make sex more comfortable.

Learn More

Vagifem

Vagifem and Yuvafem are vaginal inserts containing estradiol, an estrogen hormone. Estrogen suppositories are used primarily to treat moderate to severe menopausal symptoms in and around the vagina, such as dryness, itching, and burning.

Learn More

About the author

Saad Alam is the CEO and co-founder of Hone, a modern health optimization platform that helps men and women take charge of their hormones, metabolism, and longevity through advanced biomarker testing and personalized, clinician-guided care.

About the reviewer

Dr. James R. Staheli is the Medical Director for Broad Health, Hone Health’s affiliated medical practice and a family medicine doctor in Atlanta, Georgia.